<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>MDMA - Complete Profile</title>
    <link rel="stylesheet" href="/style.css">
</head>

<body>
  <body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/" class="site-title">Dyo's Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/">Home</a>
          </li>
          <li>
            <a href="/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/about/">About</a>
          </li>
          <li>
            <a href="/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/empathogens/">Empathogens</a> ‚Üí <span>MDMA</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üíñ MDMA</h1>
        <h2 class="chemical-name">3,4-Methylenedioxymethamphetamine</h2>
        
        <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="MDMA" 
                data-category="Empathogens" 
                data-chemical="3,4-Methylenedioxymethamphetamine">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Common Names</h4>
              <span>Ecstasy</span> ‚Ä¢ <span>Molly</span> ‚Ä¢ <span>E</span> ‚Ä¢ <span>X</span> ‚Ä¢ <span>XTC</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Pills</span> ‚Ä¢ <span>Beans</span> ‚Ä¢ <span>Rolls</span> ‚Ä¢ <span>Disco Biscuits</span> ‚Ä¢ <span>Love Drug</span>
            </div>
            <div class="name-category">
              <h4>Historical/Clinical</h4>
              <span>Adam</span> ‚Ä¢ <span>MDM</span> ‚Ä¢ <span>Methylenedioxymethamphetamine</span>
            </div>
            <div class="name-category">
              <h4>Chemical Abbreviations</h4>
              <span>MDMA-HCl</span> ‚Ä¢ <span>3,4-MDMA</span> ‚Ä¢ <span>N-methyl-MDA</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category empathogen">Empathogen</span>
          <span class="legal-status schedule-1">Schedule I</span>
          <span class="duration medium">4-6 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/mdma.jpg" alt="MDMA crystals and pills" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇÅH‚ÇÅ‚ÇÖNO‚ÇÇ</p>
            <p>MW: 193.25 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure MDMA (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder</li>
            <li><strong>Texture:</strong> Fine crystals, sometimes chunky</li>
            <li><strong>Odor:</strong> Slightly sweet, anise/licorice-like (faint)</li>
            <li><strong>Taste:</strong> Extremely bitter, numbing</li>
            <li><strong>Solubility:</strong> Highly soluble in water</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Street Forms</h4>
          <ul>
            <li><strong>Pills/Tablets:</strong> Various colors, shapes, logos (often pressed with binders)</li>
            <li><strong>"Molly" Powder:</strong> Often brown/tan due to impurities or adulterants</li>
            <li><strong>Capsules:</strong> Powder in gelatin caps, color varies</li>
            <li><strong>Crystals:</strong> Chunky crystal form, can be clear to brown</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Common Adulterants</h4>
          <p><strong>Pills:</strong> Caffeine, methylone, 4-MMC, piperazines (mCPP, BZP), MDA</p>
          <p><strong>Powder:</strong> Methylone, pentylone, N-ethylpentylone, caffeine, lactose</p>
          <p><strong>Dangerous:</strong> PMA/PMMA (deadly), methamphetamine, synthetic cathinones</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">30-50mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">50-75mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">75-125mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">125-175mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">175mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Dosage Considerations</h4>
        <ul>
          <li><strong>Weight-based:</strong> ~1-1.5mg/kg for therapeutic effects</li>
          <li><strong>Gender differences:</strong> Women may be more sensitive to effects</li>
          <li><strong>Redosing:</strong> Not recommended - increases neurotoxicity risk</li>
          <li><strong>Tolerance:</strong> Develops rapidly, take 1-3 month breaks minimum</li>
          <li><strong>First time:</strong> Start with 75-100mg maximum</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Critical Warning:</strong> "Molly" is frequently adulterated with dangerous substances. Always test with multiple reagents before use.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-1:00</span>
          <span class="effect">Onset - euphoria, energy increase</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:00-3:00</span>
          <span class="effect">Peak - intense empathy, emotional openness</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+3:00-6:00</span>
          <span class="effect">Comedown - gradual return to baseline</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+6:00-48:00</span>
          <span class="effect">After effects - possible depression, fatigue</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Positive Effects</h4>
          <ul>
            <li>Intense euphoria and wellbeing</li>
            <li>Emotional openness and empathy</li>
            <li>Enhanced sociability</li>
            <li>Increased energy and alertness</li>
            <li>Enhanced sensory perception</li>
            <li>Feelings of love and connection</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Negative Effects</h4>
          <ul>
            <li>Jaw clenching (bruxism)</li>
            <li>Eye wiggling (nystagmus)</li>
            <li>Hyperthermia</li>
            <li>Dehydration</li>
            <li>Post-experience depression</li>
            <li>Anxiety during comedown</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>MDMA is a potent triple monoamine releasing agent and reuptake inhibitor. It binds to and reverses the direction of SERT, NET, and DAT transporters, causing massive release of stored neurotransmitters while simultaneously blocking their reuptake. This creates a flood of serotonin (primarily), dopamine, and norepinephrine in synaptic clefts.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>SERT (5-HT transporter)</strong></span>
            <span class="affinity">High affinity (IC50: 0.5-1.0 ŒºM)</span>
            <span class="function">Primary empathogenic effects, emotional openness</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NET (NE transporter)</strong></span>
            <span class="affinity">Moderate affinity (IC50: 1-2 ŒºM)</span>
            <span class="function">Stimulant effects, increased energy, focus</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>DAT (DA transporter)</strong></span>
            <span class="affinity">Lower affinity (IC50: 15-30 ŒºM)</span>
            <span class="function">Euphoria, reward pathway activation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>5-HT2A receptor</strong></span>
            <span class="affinity">Weak partial agonist</span>
            <span class="function">Mild perceptual changes, some visuals</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>5-HT1A receptor</strong></span>
            <span class="affinity">Moderate agonist activity</span>
            <span class="function">Anxiolytic effects, mood regulation</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> N-demethylation by CYP2D6 ‚Üí MDA (active metabolite)</p>
          <p><strong>Secondary Pathway:</strong> O-demethylenation ‚Üí HHMA, HMA (inactive)</p>
          <p><strong>Half-life:</strong> 6-8 hours (highly variable due to CYP2D6 polymorphism)</p>
          <p><strong>Bioavailability:</strong> ~70% oral administration</p>
          <p><strong>Peak plasma:</strong> 1-3 hours after oral dose</p>
          <p><strong>Genetic factors:</strong> CYP2D6 poor metabolizers experience longer, more intense effects</p>
        </div>

        <h4>Neurotoxicity Mechanisms</h4>
        <div class="neurotoxicity-info">
          <p><strong>Serotonin terminal damage:</strong> Hyperthermia and oxidative stress cause axon terminal degeneration</p>
          <p><strong>Dopamine involvement:</strong> MDA conversion and hyperthermia increase neurotoxic potential</p>
          <p><strong>Temperature dependence:</strong> Neurotoxicity dramatically increases above 40¬∞C (104¬∞F)</p>
          <p><strong>Frequency dependence:</strong> Damage accumulates with repeated use, especially frequent dosing</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Entactogenic profile:</strong> Unique combination of empathy + energy vs. classic stimulants</li>
          <li><strong>Oxytocin release:</strong> Increased oxytocin contributes to pro-social effects</li>
          <li><strong>Vasopressin effects:</strong> May contribute to water retention/hyponatremia risk</li>
          <li><strong>Body temperature:</strong> Disrupts thermoregulation through 5-HT effects</li>
          <li><strong>Memory formation:</strong> Enhanced emotional memory consolidation during peak effects</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Temperature regulation:</strong> Can cause fatal hyperthermia</li>
            <li><strong>Serotonin syndrome:</strong> Dangerous with SSRIs, MAOIs</li>
            <li><strong>Cardiovascular stress:</strong> Risk for those with heart conditions</li>
            <li><strong>Neurotoxicity:</strong> Potential damage with frequent use</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Precautions</h4>
          <ul>
            <li>Test substances with reagent kits</li>
            <li>Stay cool and hydrated (but don't over-hydrate)</li>
            <li>Use with trusted people in safe environment</li>
            <li>Wait 1-3 months between uses</li>
            <li>Avoid if taking antidepressants</li>
            <li>Don't mix with other stimulants</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Heart conditions, high blood pressure, seizure disorders, liver problems, depression, anxiety disorders, or are taking psychiatric medications.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous</h4>
          <ul>
            <li><strong>MAOIs:</strong> Risk of serotonin syndrome and hypertensive crisis</li>
            <li><strong>SSRIs/SNRIs:</strong> Serotonin syndrome, reduced MDMA effects</li>
            <li><strong>Tramadol:</strong> Increased seizure risk, serotonin syndrome</li>
            <li><strong>DXM:</strong> Serotonin syndrome</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Risky</h4>
          <ul>
            <li><strong>Stimulants:</strong> Increased cardiovascular strain</li>
            <li><strong>Alcohol:</strong> Increased neurotoxicity, dehydration</li>
            <li><strong>Cannabis:</strong> May increase anxiety or paranoia</li>
            <li><strong>Psychedelics:</strong> Unpredictable interactions</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Caution</h4>
          <ul>
            <li><strong>2C-x compounds:</strong> Both affect serotonin</li>
            <li><strong>Tryptamines:</strong> Risk of overwhelming experience</li>
            <li><strong>Nitrous oxide:</strong> Risk of falls, oxygen deprivation</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Schedule I</strong> - Illegal to manufacture, possess, or distribute. No accepted medical use (changing with clinical trials).</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Class A</strong> - Up to 7 years for possession, life for supply. Considered most dangerous category.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá≥üá± Netherlands</h4>
            <p><strong>List I</strong> - Illegal but enforcement varies. Testing services available at festivals.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¶üá∫ Australia</h4>
            <p><strong>Schedule 9</strong> - Prohibited substance except for approved research.</p>
          </div>
        </div>
        
        <div class="therapeutic-status">
          <h4>üè• Therapeutic Status</h4>
          <p>MDMA-assisted psychotherapy is in Phase 3 clinical trials for PTSD treatment. FDA approval expected by 2024, which would make it the first psychedelic medicine available by prescription in decades.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1912</span>
          <p>First synthesized by Merck pharmaceuticals as a blood clotting agent precursor</p>
        </div>
        <div class="history-event">
          <span class="year">1976</span>
          <p>Alexander Shulgin resynthesizes and introduces to psychotherapist Leo Zeff</p>
        </div>
        <div class="history-event">
          <span class="year">1980s</span>
          <p>Used in psychotherapy as "Adam" before becoming illegal</p>
        </div>
        <div class="history-event">
          <span class="year">1985</span>
          <p>DEA emergency scheduling makes MDMA illegal</p>
        </div>
        <div class="history-event">
          <span class="year">1987</span>
          <p>Emerges in UK club scene as "Ecstasy," fuels rave culture</p>
        </div>
        <div class="history-event">
          <span class="year">2001</span>
          <p>MAPS begins FDA-approved studies for PTSD treatment</p>
        </div>
        <div class="history-event">
          <span class="year">2017</span>
          <p>FDA grants "Breakthrough Therapy" designation for PTSD</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Cultural Impact</h4>
        <p>MDMA fundamentally transformed electronic music culture, creating new forms of social bonding and community. The "rave" experience of collective euphoria and acceptance became a defining cultural movement of the 1990s and continues to influence festival culture worldwide.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>PTSD Treatment</h4>
          <p>Phase 3 trials show 67% of participants no longer meeting PTSD criteria after MDMA-assisted therapy. This represents the most significant breakthrough in trauma treatment in decades.</p>
        </div>
        
        <div class="research-item">
          <h4>Autism Social Anxiety</h4>
          <p>Ongoing research into MDMA's potential for treating social anxiety in autistic adults, leveraging its empathogenic properties.</p>
        </div>
        
        <div class="research-item">
          <h4>Couples Therapy</h4>
          <p>Preliminary research suggests MDMA may enhance couples therapy by increasing emotional openness and reducing defensive responses.</p>
        </div>
        
        <div class="research-item">
          <h4>End-of-Life Anxiety</h4>
          <p>Early studies examining MDMA's potential for reducing anxiety in terminally ill patients.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Testing Services</h4>
        <ul>
          <li><a href="https://drugsdata.org/">DrugsData.org</a> - Lab testing service</li>
          <li><a href="https://bunkpolice.com/">The Bunk Police</a> - Reagent test kits</li>
          <li><a href="https://dancesafe.org/">DanceSafe</a> - Harm reduction at events</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Educational Resources</h4>
        <ul>
          <li><a href="https://maps.org/">MAPS</a> - Research and education</li>
          <li><a href="https://rollsafe.org/">RollSafe</a> - MDMA harm reduction guide</li>
          <li><a href="https://psychonautwiki.org/">PsychonautWiki</a> - Comprehensive drug information</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Community</h4>
        <ul>
          <li><a href="https://reddit.com/r/MDMA">/r/MDMA</a> - Community discussion</li>
          <li><a href="https://bluelight.org/">Bluelight</a> - Harm reduction forum</li>
          <li><a href="https://erowid.org/">Erowid</a> - Experience reports and information</li>
        </ul>
      </div>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/js/lunr.min.js"></script>
    <script src="/assets/js/search.js"></script>
    <script src="/assets/js/substance-integration.js"></script>
</body>
</html>